A Hims ad in a Brooklyn subway car this month reads "$39 for your first month." Squint at the fine print and you catch the $199 that kicks in after. The molecule behind it is semaglutide — Novo Nordisk's, the real thing, not a compounded copy — and the Wegovy pill sits on the eligible drug list. Nine months ago that poster would have drawn a lawsuit, if it ran at all.
That's the third full reset of the US direct-to-consumer GLP-1 market in 13 months. If you started paying attention in early 2025, the rules you learned are already wrong. If you're staring at a Wegovy refill that ran $599 last spring and $349 through NovoCare last fall, the May 2026 answer to "what's the cheapest legal way to actually get this" has moved again.
Below: what the March 2026 Novo–Hims collaboration sells you, what NovoCare is doing on the other counter, where the compounded-semaglutide underground went, and — because the rest of the world watches this market like a test kitchen — which parts travel and which don't.
The dollar figure in your pocket, May 2026
Strip the press releases and look at line items.
| Path | What you get | Monthly cost | Who qualifies |
|---|---|---|---|
| Hims Weight Loss — new membership | Round-the-clock clinician access, coaching, FDA-approved GLP-1 including Wegovy oral 25 mg for eligible members | $39 first month, $199 after | Adults with BMI 30+, or 27+ with comorbidity; clinical eligibility gated by the Hims medical team |
| NovoCare Pharmacy — direct cash | All Wegovy injector doses (0.25 / 0.5 / 1 / 1.7 / 2.4 mg), CenterWell fulfills | $499 / month, every dose | Cash pay only; not Medicare, Medicaid, or commercial insurance |
| Wegovy list price (retail) | Injector, all doses | ~$1,350 / month | Cash baseline without a coupon |
| LillyDirect — Foundayo (orforglipron pill) | Oral GLP-1, no food or water timing | ~$149 / month at launch | BMI 30+, or 27+ with comorbidity |
| Medicare GLP-1 Bridge — opens July 1, 2026 | Wegovy or Zepbound through Part D | $50 / month | Medicare beneficiaries meeting SELECT or SURMOUNT-OSA criteria |
Notice what that means. The Hims tier runs close to what many commercial plans charge as a specialty-drug copay, and NovoCare at $499 remains less than half of list — yet the Hims bundle already undercuts NovoCare on a straight headline read.
Headline isn't the whole story. Hims' $39-then-$199 is a membership fee that buys clinician time, messaging, coaching, and the drug itself for eligible members. NovoCare's $499 is the drug, full stop — you bring your own prescriber. Foundayo's ~$149 through LillyDirect is also drug-only, and it's an entirely different molecule with its own trial record. Pricing them against each other on a single line is like stacking a gym membership next to a barbell. Related. Not the same purchase.
The cheapest number on the table is the one with the most conditions attached. "$39 for your first month" is real. It's also a 30-day preview of a $199 recurring charge, with eligibility the Hims medical team decides after you submit your intake.
The 13 months that got us here
Walk it backwards, because the sequence matters. Skip the middle and the March 2026 deal looks like a fresh idea. It's a rerun with edits.
April 2025. Novo Nordisk and Hims & Hers announced their first collaboration. Branded Wegovy, shipped through Hims, $599 a month. At the time, that was a real discount versus the ~$1,350 list — and a signal that Big Pharma was willing to cut DTC partners in beyond its own NovoCare channel.
June 2025. Novo pulled the plug. The public reason: Hims was also selling and promoting compounded semaglutide — the 503A/503B pharmacy copies that bloomed during the 2022–2024 shortage. HIMS stock dropped roughly 30–34% that day. The partnership imploded inside ten weeks.
Through 2025. FDA's transitional enforcement windows for compounded semaglutide expired in stages. Semaglutide came off the shortage list in February 2025; tirzepatide had come off in December 2024. Once both were officially "available," 503A personalized-compounding and 503B outsourcing-facility copies lost the legal cover that had justified mass telehealth marketing. Warning letters escalated through the year.
December 22, 2025. FDA approved Wegovy oral 25 mg for chronic weight management. Same molecule as the Wegovy injector, different form factor. Novo launched it in the US on January 5, 2026.
March 2026. Novo dropped its patent-infringement suit against Hims. Hims agreed to stop promoting compounded GLP-1. Both sides announced a new collaboration. The headline landed at $39 for the first month and $149 thereafter, and the program explicitly includes FDA-approved GLP-1s — with the Wegovy pill as the newsworthy addition.
April 1, 2026. FDA approved Foundayo (orforglipron, Lilly) for chronic weight management. Launch cash price through LillyDirect: roughly $149 a month. Same number as Hims' month-two bill, but a different drug from a different company.
Four resets in 13 months, each one shifting who could sell what to whom and at what price. Anyone who hasn't refreshed their mental map since last summer is working from an expired version.
What Hims actually sells you now
The membership is the product. The drug is one tool inside it.
Sign up at Hims in May 2026 and you're buying access to a virtual clinic. A licensed prescriber in your state handles the intake — medical history, BMI, comorbidities, medications you're already on, labs if your state requires them. If you qualify clinically and the provider agrees a GLP-1 is the right call, the specific drug gets assigned from Hims' eligible list. That list now includes branded Wegovy and the new Wegovy oral 25 mg tablet, plus the non-GLP-1 weight-loss options Hims already offered.
You also get messaging with the care team — technically around the clock, though the useful-response window is usually business hours — plus the nutrition and exercise coaching layer the company has built over the past two years. If you've used any DTC weight-loss service since 2023, the shape of this is familiar.
Month-one is $39. Every month after is $149, billed monthly, no long commitment. Cancel and you stop. Miss a month and your prescription pipeline pauses. If your provider changes the drug — you start on the Wegovy injector and titrate up, or move onto oral Wegovy later — the membership price doesn't move.
A few things aren't in the bundle. Labs your state or provider require can be separate. Specialty compounding isn't offered — that's the whole point of the new agreement. If Novo ever pulls Wegovy oral from the eligible list, your options shift to whatever remains.
One detail worth flagging. A Hims weight-loss membership at $149 is not the same as a standalone Wegovy prescription at $149. You're paying for a bundle that includes the drug for eligible members. If your clinical picture pushes the provider toward a non-Wegovy option, or if you're not a GLP-1 candidate at all, the $149 still buys the membership. It's a service fee with drug access attached, not a pharmacy counter transaction.
NovoCare on the other counter
NovoCare Pharmacy launched in March 2025 as Novo's own direct channel. The pitch is simpler: cash pay, no insurance, no membership, just the drug.
All five Wegovy doses — 0.25, 0.5, 1, 1.7, and 2.4 mg — ship for $499 a month. Flat across titration, which matters because your first three months on Wegovy are dose escalation and your fourth month onward is maintenance. The list price reference point is roughly $1,350 a month. Commercial insurance with a decent formulary tier might land you at $25 to $50 after copay. NovoCare sits in the middle, for people whose insurance won't cover it at all.
Fulfillment goes through CenterWell Pharmacy. You need a prescription from a clinician — NovoCare doesn't provide one. Hims does. So the two channels solve different problems. NovoCare is the cheapest way to get branded Wegovy injector when you already have a prescriber and cash on hand. Hims is the cheapest way to get a prescriber, a plan, and a drug in one click.
The disqualifiers are strict. NovoCare's terms explicitly exclude Medicare, Medicaid, and anyone using commercial insurance on the same fill. If your plan covers Wegovy at $50 a month after deductible, you're supposed to use that, not NovoCare. The channel exists for the tens of millions of US adults whose plans don't cover obesity meds at all, or who work outside employer insurance entirely.
What happens to compounded semaglutide in May 2026
Short version: the legal window closed in 2025, and by May 2026 any clinic still marketing compounded GLP-1 at scale is operating in a different regulatory zone than it was a year ago.
The compounded-semaglutide boom ran from roughly mid-2022 to early 2025, riding FDA's shortage declaration. When a drug is on the shortage list, 503A personalized-compounding pharmacies and 503B outsourcing facilities get a legal pathway to make copies. That's how the telehealth category — Ro, Hims, Henry Meds, and dozens of smaller brands — built a compounded-semaglutide business in the first place.
Tirzepatide came off shortage in December 2024. Semaglutide came off in February 2025. FDA granted transitional grace periods — not the same length for each, and the details filled multiple enforcement letters — and those windows expired through 2025. By January 2026, mass telehealth marketing of compounded semaglutide was no longer defensible under the shortage exemption.
What that means on the ground in May 2026:
- Hims has exited compounded GLP-1. That's the explicit condition Novo set before the March agreement went live. The old compounded SKU is gone.
- Some smaller telehealth brands still offer it. Enforcement isn't uniform. FDA and state boards of pharmacy have written warnings; individual clinics are still shipping. Legal risk to the clinic doesn't equal legal risk to the patient, but supply can vanish on short notice.
- Patient-specific compounding for documented medical need remains legal. The narrow 503A carve-out: a clinician who can document that a specific patient can't use the commercial product for a real clinical reason can still get a compounded prescription. A different universe from the mass-market $129/month subscription.
- The price gap narrowed. When compounded semaglutide was $99 to $199 a month and branded Wegovy cash was $1,350, the economics sold themselves. With Hims at $149 including clinician care, NovoCare at $499, and Foundayo at $149 through LillyDirect, the branded-vs-compounded delta is mostly gone for the average user.
For a US patient in May 2026, the practical question isn't "can I find compounded semaglutide." It's "why would I, when the legal options land at roughly the same price and they don't disappear when your clinic gets a cease-and-desist." The compounded-vs-branded fight that powered last year's Hims-Novo drama is, on the margin, a solved problem — because branded pricing finally moved.
The July 1 Medicare flip, and why it matters here
The GLP-1 Bridge program opens July 1, 2026. Eligible Medicare Part D beneficiaries get Wegovy and Zepbound for $50 a month. The clinical gate is BMI ≥30, or BMI ≥27 with a qualifying comorbidity like established cardiovascular disease (SELECT criteria) or moderate-to-severe obstructive sleep apnea (SURMOUNT-OSA criteria).
Roughly 67 million people are enrolled in Medicare Part D. Not all will qualify. Not all who qualify will fill. Analyst estimates for net new prescriptions, as of May 2026, cluster in a range of about 3 to 8 million over the first 18 months.
Why this matters for the DTC story. Medicare doesn't just pick up a segment the DTC channels weren't serving — it pulls people out of the NovoCare and Hims cash-pay funnel and sends them back through Part D. Anyone over 65 who was paying Hims $149 a month in May for Wegovy access gets a better deal on July 1 by running the prescription through Part D. Worth bringing up with your clinician if that's you.
The March deal reset the US retail price. The July Medicare flip resets the reference price. Two different levers, pulling in the same direction, inside four months.
A ripple runs the other way too. If Medicare uptake pulls US injector supply tight — and 3 million new Part D fills on top of current demand could — NovoCare and Hims both get squeezed on allocation. Novo has said through 2025 that US-bound Wegovy supply is prioritized, but "prioritized" is a relative word when total demand sits above capacity. A Hims member on Wegovy injector in September 2026 is in a different queue than a member on Wegovy oral. That's the quiet pitch for the oral tablet embedded in this whole arrangement.
How the US playbook travels — and where it doesn't
The Hims-Novo story is a US story. The compounded-GLP-1 underground that triggered it barely exists outside the US, which is why most global readers watching the March 2026 press release didn't recognize the drama underneath it.
Quick map of the majors, as of May 2026:
| Market | Semaglutide (obesity) brand | Legal mass-market compounded channel? | DTC pharma pharmacy? |
|---|---|---|---|
| United States | Wegovy (inj + oral 25 mg) | Narrow, patient-specific only | Yes — NovoCare, LillyDirect |
| United Kingdom | Wegovy | No mass-market channel | Not in the US form |
| European Union | Wegovy | Generally no | Limited, country by country |
| South Korea | 위고비 | No | Emerging via Novo Korea |
| Japan | ウゴービ | No | Not established |
| China mainland | 诺和盈 | No | Domestic channel different |
Three takeaways worth naming.
The US is unusual because shortage-era compounding created a legitimate parallel market and then FDA closed it. Most of the rest of the world never opened that door; their telehealth clinics couldn't legally sell compounded semaglutide at scale even during the global shortage. So the Hims-Novo detente solves a problem most countries don't have.
The UK is the closest secondary reader. NHS Wegovy rollout has been slow since 2023, Harley Street private clinics run cash-pay at £200–£280 a month, and Boots and Lloyds Pharmacy online services have been the main DTC-style channel. Novo has no UK equivalent of NovoCare as of May 2026. A Hims-style bundle priced in pounds doesn't yet exist; when it does, expect it to look a lot like what just settled in the US.
Direct-to-patient pharma pharmacies modeled on NovoCare are starting to appear in a handful of markets — Germany and Australia have the closest-fit regulatory environments — but none of them carry the US's specific combination: a commercial insurance base that doesn't cover obesity, and a Medicare program that until this year didn't either. That combination is what made DTC a category in the first place. It's why the US is still the test market.
Questions to bring to your clinician
A starter list for anyone sitting with the May 2026 version of this decision:
- Which of the three legal US paths — Hims bundle, NovoCare cash, commercial insurance — gives me the lowest out-of-pocket in my actual plan? Run the math for 6 and 12 months, not just month one.
- If I'm on Medicare or turning 65 this year, does July 1 change my plan? Ask whether your Part D plan is filing the paperwork for the GLP-1 Bridge program and what the formulary tier will be.
- Am I a candidate for the Wegovy oral tablet rather than the injector? The two share a molecule, but titration, timing, and the side-effect curve are different.
- If I start with Hims and want to switch prescribers later, does my prescription history transfer cleanly, or am I starting over? This matters more than people realize until they try to move.
- Is Foundayo (orforglipron) on the table? It's newer than Wegovy, the pricing is comparable through LillyDirect, and the no-food-no-water pill regimen is a real quality-of-life difference if it suits you.
- For someone still on compounded semaglutide: is there a defensible clinical reason, or is this just momentum? If it's momentum, the switch window is now, not when the clinic gets a letter.
That last bullet isn't a scare line. Any telehealth brand still shipping mass-market compounded GLP-1 in May 2026 is making a different bet than it was making in 2023.
What to watch before you commit to a plan
Five things that can move the price you pay between now and the end of 2026.
The July 1 Medicare flip is the biggest single variable. It moves demand. It moves supply. Watch the FDA drug shortage database through Q3 — re-listing of semaglutide or tirzepatide is the earliest public signal the injector side is in trouble. If that happens, Hims members on the Wegovy injector are in a different queue than members on Wegovy oral, and Foundayo at LillyDirect becomes a real backup rather than an alternative.
The Hims membership has been $149 a month since launch, but the company has flexibility on promo pricing and bundle composition. The $39 first month is a promotion. Assume it stays available through at least Q4, then watch the renewal math.
NovoCare hasn't changed its $499 flat-dose price since March 2025. If Medicare net prices come in notably below $499 when the July program goes live, downward pressure on NovoCare's cash number looks plausible by 2027. Not guaranteed.
Foundayo is new — it launched April 1, 2026 — and the ~$149 cash price through LillyDirect is Lilly's launch positioning, not a long commitment. Watch for updates after the first 12 to 18 months of real-world data.
And the court and FDA docket. The Hims-Novo suit is settled, but individual state boards of pharmacy are still moving on compounded-GLP-1 marketing. The telehealth brand that's cheap in June might be gone in October.
What's next
Three dates on the calendar. July 1, 2026 — Medicare GLP-1 Bridge opens. Q4 2026 earnings season — Novo and Lilly will report US DTC channel volumes, and the Hims-Novo partnership will have six full months on the books. Spring 2027 — the first round of federal price-setting tied to CMS negotiation authority touches adjacent drug categories, and the template matters for what GLP-1 pricing looks like the year after.
For US readers, the practical takeaway for May 2026 is narrower than any press release makes it sound. You have more legal options than a year ago. The cheapest headline — $39 for month one with Hims — buys you a legitimate entry point that didn't exist last summer. Past month two, the $149 membership is, for most people, still the cheapest legal path to a branded GLP-1 without insurance. NovoCare at $499 is the play if you already have a prescriber. Medicare at $50 is the play on July 1 if you qualify. And the compounded underground that powered last year's story is a smaller, riskier market than it was — which is the closest thing the DTC category has had to stability since this all started.
The rest of the world will read the March 2026 deal like a preview of the next couple of years. Most of it won't translate directly, because most of it is downstream of a uniquely US regulatory accident. The piece that will travel is the direction of pricing — downward, and faster than pharma's old playbook said it should move.
Start managing your GLP-1 with Blueshot
AI coaching, injection scheduling, and weight tracking in one app
